1
|
Mothapo KM, Ten Oever J, Koopmans P, Stelma FF, Burm S, Bajramovic J, Verbeek MM, Rikkert MGO, Netea MG, Koopman G, van der Ven AJ. Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions. J Neurovirol 2016; 23:250-259. [PMID: 27882497 DOI: 10.1007/s13365-016-0495-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 10/18/2016] [Accepted: 10/20/2016] [Indexed: 11/29/2022]
Abstract
HIV in the central nervous system (CNS) mainly infects microglial cells which are known to express toll-like receptors (TLRs). This paper aimed to study the role of soluble TLR2 (sTLR2), sTLR4, and other inflammatory markers in cerebrospinal fluid (CSF) in HIV/Simian immunodeficiency virus (SIV)-related neurological sequelae. We determined sTLR2 and sTLR4 levels in CSF and serum/plasma of SIV-infected rhesus macaques with and without neurological sequelae, as well as in HIV-infected patients with and without cognitive impairments and Alzheimer's disease (AD) patients and matched controls. CSF cytokines and chemokines levels were analyzed in macaques as markers of neuroinflammation, while neopterin and S100B CSF concentrations were measured in HIV-infected patients as microglial and astrocyte marker, respectively. We found detectable levels of sTLR2 and sTLR4 in CSF of macaques and humans. Furthermore, CSF sTLR2 and sTLR4 concentrations were higher in SIV-infected macaques with neurological sequelae compared to those without neurological complications (p = 0.0003 and p = 0.0006, respectively). CSF IL-8 and monocyte chemoattractant protein-1 (MCP-1) levels were elevated in macaques with neurological sequelae, and a positive correlation was found between CSF levels of sTLR2/4 and IL-8 and MCP-1. Also in humans, elevated CSF sTLR4 levels were found in HIV-infected patients with cognitive impairments compared to HIV-infected patients with normal cognition (p = 0.019). Unlike CSF S100B levels, neopterin correlated positively with sTLR2 and sTLR4. No difference was found in plasma and CSF sTLR2 and sTLR4 levels between AD patients and control subjects (p = 0.26). In conclusion, CSF sTLR2 and sTLR4 may play a role in HIV/SIV-related neuroinflammation and subsequent neuropathology.
Collapse
Affiliation(s)
- Khutso M Mothapo
- Department of Internal Medicine and Nijmegen Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
| | - J Ten Oever
- Department of Internal Medicine and Nijmegen Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
| | - P Koopmans
- Department of Internal Medicine and Nijmegen Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
| | - F F Stelma
- Department of Medical Microbiology-Section Virology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - S Burm
- Alternatives Unit, Biomedical Primate Research Centre, Rijswijk, The Netherlands
| | - J Bajramovic
- Alternatives Unit, Biomedical Primate Research Centre, Rijswijk, The Netherlands
| | - M M Verbeek
- Departments of Neurology and Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
| | - M G Olde Rikkert
- Radboudumc Alzheimer Centre, Department of Geriatric Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - M G Netea
- Department of Internal Medicine and Nijmegen Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
| | - G Koopman
- Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands
| | - A J van der Ven
- Department of Internal Medicine and Nijmegen Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
| |
Collapse
|
2
|
Weijsenfeld AM, Smit C, Cohen S, Wit FWNM, Mutschelknauss M, van der Knaap LC, van Zonneveld LM, Zomer BJ, Nauta N, Patist JC, Kuipers-Jansen MHJ, Smit EP, Blokhuis C, Pajkrt D, Weijsenfeld AM, Cohen S, Blokhuis C, van der Plas A, Scherpbier HJ, Mutschelknauss M, Nellen FJB, Prins JM, Pajkrt D, Smit C, Wit FWNM, Reiss P, van der Knaap L, Visser E, van Zonneveld LM, Vriesde ME, Bassant NY, van der Ende ME, van Rossum AMC, Driessen GJA, Fraaij PLA, Smit JV, Smit EP, Kastelijns MPW, den Hollander JG, Pogány K, Moons C, Kroon FP, Oude Geerdink E, van der Meche IB, Schouten WEM, Brinkman K, Ter Beest G, Gisolf EH, Richter C, Zomer BJ, Strik-Albers R, van der Flier M, Henriet SS, Koopmans PP, Patist JC, Nauta N, Geelen SPM, Wolfs TFW, Hoepelman IM, Mudrikova T, van der Meulen PA, de Jonge H, Scholvink EH, Bierman WFW, van den Berg JF, Bouwhuis JW, Faber S, van Vonderen M, Schippers JA, Lowe SH, Kuipers-Jansen MHJ, van Kasteren MEE, Brouwer AE, Pronk DC, Kortmann W. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care. Clin Infect Dis 2016; 63:1105-1112. [PMID: 27439528 DOI: 10.1093/cid/ciw487] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 07/06/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND As a result of effective combination antiretroviral therapy (cART) and advanced supportive healthcare, a growing number of human immunodeficiency virus (HIV)-infected children survive into adulthood. The period of transition to adult care is often associated with impaired adherence to treatment and discontinuity of care. We aimed to evaluate virological and social outcomes of HIV-infected adolescents and young adults (AYAs) before and after transition, and explore which factors are associated with virological failure. METHODS We included 59 HIV-infected AYAs from the Netherlands who had entered into pediatric care and transitioned from pediatric to adult healthcare. We used HIV RNA load and cART data from the Dutch Stichting HIV Monitoring database (1996-2014), and collected social and treatment data from patients' medical records from all Dutch pediatric HIV treatment centers and 14 Dutch adult treatment centers involved. We evaluated risk factors for virological failure (VF) in a logistic regression model adjusted for repeated measurements. RESULTS HIV VF occurred frequently during the study period (14%-36%). During the transition period (from 18 to 19 years of age) there was a significant increase in VF compared with the reference group of children aged 12-13 years (odds ratio, 4.26 [95% confidence interval, 1.12-16.28]; P = .03). Characteristics significantly associated with VF were low educational attainment and lack of autonomy regarding medication adherence at transition. CONCLUSIONS HIV-infected AYAs are vulnerable to VF, especially during the transition period. Identification of HIV-infected adolescents at high risk for VF might help to improve treatment success in this group.
Collapse
Affiliation(s)
- Annouschka M Weijsenfeld
- Department of Pediatric Infectious Diseases, Emma Children's Hospital, Academic Medical Centre AMC
| | | | - Sophie Cohen
- Department of Pediatric Infectious Diseases, Emma Children's Hospital, Academic Medical Centre AMC
| | - Ferdinand W N M Wit
- HIV Monitoring Foundation.,Department of Infectious Diseases, Academic Medical Center AMC, Amsterdam
| | | | - Linda C van der Knaap
- Department of Pediatrics, Division of Infectious Diseases and Immunology, Erasmus Medical Centre-Sophia Children's Hospital
| | | | - Bert J Zomer
- Department of Infectious Diseases, Radboud University Medical Centre, Nijmegen
| | - Nike Nauta
- Department of Pediatric Infectious Diseases, Wilhelmina Children's Hospital
| | - Joke C Patist
- Department of Internal Medicine and Infectious Diseases, University Medical Centre UMC, Utrecht
| | | | - Esther P Smit
- Department of Infectious Diseases, Maasstad Hospital, Rotterdam, The Netherlands
| | - Charlotte Blokhuis
- Department of Pediatric Infectious Diseases, Emma Children's Hospital, Academic Medical Centre AMC
| | - Dasja Pajkrt
- Department of Pediatric Infectious Diseases, Emma Children's Hospital, Academic Medical Centre AMC
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Hullegie SJ, van den Berk GEL, Leyten EMS, Arends JE, Lauw FN, van der Meer JTM, Posthouwer D, van Eeden A, Koopmans PP, Richter C, van Kasteren MEE, Kroon FP, Bierman WFW, Groeneveld PHP, Lettinga KD, Soetekouw R, Peters EJG, Verhagen DWM, van Sighem AI, Claassen MAA, Rijnders BJA. Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014. Clin Microbiol Infect 2015; 22:209.e1-209.e3. [PMID: 26482267 DOI: 10.1016/j.cmi.2015.10.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Revised: 10/07/2015] [Accepted: 10/09/2015] [Indexed: 10/22/2022]
Abstract
Within the Dutch Acute HCV in HIV Study, a surveillance system was initiated to estimate the incidence of hepatitis C virus (HCV) infections in 2014. Following the Dutch HIV treatment guidelines, HIV-positive men having sex with men (MSM) in 19 participating centers were screened. Ninety-nine acute HCV infections were reported, which resulted in a mean incidence of 11 per 1000 patient-years of follow-up. Unfortunately, the HCV epidemic among Dutch HIV-positive MSM is not coming to a halt.
Collapse
Affiliation(s)
- S J Hullegie
- Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
| | - G E L van den Berk
- Department of Internal Medicine and Infectious Diseases, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
| | - E M S Leyten
- Department of Internal Medicine and Infectious Diseases, Medisch Centrum Haaglanden, Den Haag, The Netherlands
| | - J E Arends
- Department of Internal Medicine and Infectious Diseases, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands
| | - F N Lauw
- Department of Internal Medicine and Infectious Diseases, Slotervaart Ziekenhuis, Amsterdam, The Netherlands
| | - J T M van der Meer
- Department of Internal Medicine and Infectious Diseases, Academisch Medisch Centrum, Amsterdam, The Netherlands
| | - D Posthouwer
- Department of Internal Medicine and Infectious Diseases, Maastricht Universitair Medisch Centrum, Maastricht, The Netherlands
| | | | - P P Koopmans
- Department of Internal Medicine and Infectious Diseases, Radboud Universitair Medisch Centrum, Nijmegen, The Netherlands
| | - C Richter
- Department of Internal Medicine and Infectious Diseases, Rijnstate Ziekenhuis, Arnhem, The Netherlands
| | - M E E van Kasteren
- Department of Internal Medicine and Infectious Diseases, Elisabeth Ziekenhuis, Tilburg, The Netherlands
| | - F P Kroon
- Department of Internal Medicine and Infectious Diseases, Leids Universitair Medisch Centrum, Leiden, The Netherlands
| | - W F W Bierman
- Department of Internal Medicine and Infectious Diseases, University of Groningen, Universitair Medisch Centrum Groningen, Groningen, The Netherlands
| | - P H P Groeneveld
- Department of Internal Medicine and Infectious Diseases, Isala Klinieken, Zwolle, The Netherlands
| | - K D Lettinga
- Department of Internal Medicine and Infectious Diseases, Sint Lucas Andreas Ziekenhuis, Amsterdam, The Netherlands
| | - R Soetekouw
- Department of Internal Medicine and Infectious Diseases, Kennemer Gasthuis, Haarlem, The Netherlands
| | - E J G Peters
- Department of Internal Medicine and Infectious Diseases, VU Medisch Centrum, Amsterdam, The Netherlands
| | - D W M Verhagen
- Department of Internal Medicine and Infectious Diseases, Jan van Goyen Kliniek, Amsterdam
| | | | - M A A Claassen
- Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
| | - B J A Rijnders
- Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
| |
Collapse
|
4
|
Mothapo KM, Stelma F, Janssen M, Kessels R, Miners S, Verbeek MM, Koopmans P, van der Ven A. Amyloid beta-42 (Aβ-42), neprilysin and cytokine levels. A pilot study in patients with HIV related cognitive impairments. J Neuroimmunol 2015; 282:73-9. [PMID: 25903731 DOI: 10.1016/j.jneuroim.2015.03.017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 03/18/2015] [Accepted: 03/20/2015] [Indexed: 01/13/2023]
Abstract
HIV-associated dementia (HAD) is associated with amyloid-beta (Aβ) deposition. This study measured CSF and plasma amyloid beta-42 (Aβ-42), neprilysin (NEP) and cytokine levels in HIV-related cognitive impairments (HCI), HIV normal cognitive functioning (NF) and non-HIV controls. Our data showed a trend towards detectable plasma Aβ-42 levels more frequently in HCI (67%), when compared to NF (29%) and controls (10%). We showed elevated IL-8 levels in CSF of HCI compared to NF, although not significant values. The data from this pilot study indicates that CSF IL-8 and plasma Aβ-42 may be interesting biomarkers for the presence of HCI.
Collapse
Affiliation(s)
- K M Mothapo
- Department of Internal Medicine and Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Medical Center, The Netherlands.
| | - F Stelma
- Department of Virology, Radboud University Nijmegen Medical Center, The Netherlands
| | - M Janssen
- Department of Medical Psychology, Radboud University Nijmegen Medical Center, The Netherlands
| | - R Kessels
- Department of Medical Psychology, Radboud University Nijmegen Medical Center, The Netherlands
| | - S Miners
- Dementia Research Group, University of Bristol, Institute of Clinical Neurosciences, Level 1, Learning and Research, Southmead Hospital, Bristol, UK
| | - M M Verbeek
- Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; Department of Laboratory Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
| | - P Koopmans
- Department of Internal Medicine and Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Medical Center, The Netherlands
| | - A van der Ven
- Department of Internal Medicine and Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Medical Center, The Netherlands
| |
Collapse
|
5
|
Janssen MAM, Bosch M, Koopmans PP, Kessels RPC. Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients. J Neurovirol 2015; 21:383-90. [PMID: 25678141 PMCID: PMC4510920 DOI: 10.1007/s13365-015-0324-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Revised: 01/22/2015] [Accepted: 01/28/2015] [Indexed: 11/29/2022]
Abstract
The gold standard for evaluating cognitive impairments in HIV-infected patients is to administer an extensive neuropsychological assessment. This may, however, be time-consuming and hence not always feasible in the clinic. Therefore, several brief screening tools have been developed. This study determined the validity of the Montreal Cognitive Assessment (MoCA) and the HIV Dementia Scale (HDS) in detecting cognitive impairment using both the Frascati and cognitive impairment, no dementia (CIND) criteria to classify cognitive impairment in HIV-1 infected patients. The MoCA, HDS, and an extensive neuropsychological assessment, covering nine cognitive domains, were administered in a group of 102 HIV-infected patients who were all on cART and virologically suppressed for at least 1 year. Results show that the areas under the curve (AUCs) for both the MoCA and the HDS were statistically significant, using both the Frascati and the CIND criteria as gold standard. However, the AUCs for the MoCA and HDS did not differ significantly, regardless of the used classification criteria (Frascati: z = 0.37, p = 0.35; CIND: z = -0.62, p = 0.27). Sensitivity of both the MoCA and HDS were low for the recommended cutoff scores (Frascati: MoCA (<26) = 0.56, HDS (<11) = 0.26; CIND: MoCA (<26) = 0.55, HDS (<11) = 0.36). Cutoff scores with good sensitivity and adequate specificity could not be determined for both screening instruments. Therefore, the HDS and MoCA are not recommended as sole instruments to diagnose HIV-associated cognitive impairment.
Collapse
Affiliation(s)
- M A M Janssen
- Department of Medical Psychology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands,
| | | | | | | |
Collapse
|
6
|
Lowe SH, Wensing AMJ, Hassink EAM, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JMA, Borleffs JCC. Comparison of Two Once-Daily Regimens with a Regimen Consisting of Nelfinavir, Didanosine, and Stavudine in Antiretroviral Therapy-Naïve Adults: 48-Week Results from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clinical Trials 2015; 6:235-45. [PMID: 16306030 DOI: 10.1310/a686-m37y-j2pt-e9gj] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen. METHOD HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or simplified once-daily dosed antiretroviral regimens consisting of nevirapine, didanosine, and lamivudine (regimen B) or saquinavir, ritonavir, didanosine, and lamivudine (regimen C). RESULTS At 48 weeks of therapy, the proportion of patients with a blood plasma HIV-1 RNA concentration (pVL) <50 copies/mL by intention-to treat analysis was 42.3%, 50.0%, and 56.5% for regimens A (n = 26), B (n = 22), and C (n = 23), respectively. The time to a pVL <50 copies/mL for the first time was significantly shorter in regimen C, and there was significantly more progression to CDC events in regimen B. These differences are possibly due to differences in baseline characteristics. Adverse events were lowest for regimen C; more signs associated with mitochondrial toxicity occurred in regimen A. Increase in CD4 count was comparable between arms. CONCLUSION No statistically significant difference in efficacy was found between the two investigated once-daily dosed treatment regimens (B and C) and the reference (A). Regimen C possibly had a better virological response and less toxicity than regimens A and B.
Collapse
Affiliation(s)
- S H Lowe
- International Antiviral Therapy Evaluation Center (IATEC), University of Amsterdam, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Sprenger HG, Langebeek N, Mulder PGH, Ten Napel CHH, Vriesendorp R, Hoepelman AIM, Legrand JC, Koopmans PP, Bravenboer B, Ten Kate RW, Groeneveld P, Bierman W, van der Werf T, Gisolf E, Richter C. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study. HIV Med 2014; 16:122-31. [PMID: 25472825 DOI: 10.1111/hiv.12186] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/29/2014] [Indexed: 12/13/2022]
Abstract
OBJECTIVES The aim of the study was to test the antiviral efficacy of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen, with potential beneficial metabolic effects, as maintenance therapy after induction with dual NRTIs and a boosted protease inhibitor (PI). METHODS An open-label, noninferiority study was carried out. Antiretroviral therapy (ART)-naïve patients with CD4 count ≤ 350 cells/μL and HIV-1 RNA >30000 copies/mL (n=207) were treated with zidovudine/lamivudine and lopinavir/ritonavir. After achieving HIV-1 RNA <50 copies/mL on two consecutive occasions between weeks 12 and 24 after baseline, 120 patients (baseline: median HIV-1 RNA 5.19 log10 copies/mL; median CD4 count 180 cells/μL) were randomized to receive abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) (n=61) or to continue the PI-based ART (n=59). RESULTS For the proportions of patients (intention-to-treat; missing=failure) with HIV-1 RNA <400 copies/mL (PI group, 66%; ABC/3TC/ZDV group, 71%) and <50 copies/mL (PI group, 63%; ABC/3TC/ZDV group, 62%) at 96 weeks, switching to ABC/3TC/ZDV was noninferior compared with continuing the PI regimen; the difference in failure rate (ABC/3TC/ZDV minus PI) was -4.4 percentage points [95% confidence interval (CI) -21.0 to +12.3 percentage points] and +0.4 percentage points (95% CI -16.9 to +17.7 percentage points), respectively. In the per protocol analysis, the difference in virological failure for HIV-1 RNA >400 copies/mL (0 of 39 patients in the PI group and two of 45 patients in the NRTI group) and for HIV-1 RNA >50 copies/mL (two of 39 and three of 45 patients, respectively) was +4.4 percentage points (95% CI -2.1 to +11.0 percentage points) and +1.5 percentage points (95% CI -8.6 to +11.7 percentage points), respectively, also showing noninferiority. Serum lipids significantly improved in the NRTI group, but not in the PI arm. CONCLUSIONS A single-class NRTI regimen after successful induction with standard ART had similar antiviral efficacy compared to continuation of a PI-based regimen at 96 weeks after baseline, with improved serum lipids.
Collapse
Affiliation(s)
- H G Sprenger
- Department of Internal Medicine, Division of General Internal Medicine and Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Janssen MAM, Bertens D, Kessels L, Kessels RPC, Koopmans PP. A case-control pilot study on cognitive functioning, symptom validity and psychological wellbeing in HIV-1-infected patients in the Netherlands. Int J STD AIDS 2013; 24:387-91. [PMID: 23970707 DOI: 10.1177/0956462412472802] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The objective of this study was to examine and relate both cognitive functioning and psychological wellbeing in Dutch HIV-1-infected patients (n = 30) in comparison with a matched healthy control group (n = 30), taking symptom validity into account. Significant differences in performance between patients and controls were found in the domain Working memory (P = 0.036), but not in the other cognitive domains. There was a significant difference in all dimensions of the psychological wellbeing scale, measured with the SCL-90-R (P values between 0.002 and 0.023), except for agoraphobia, cognitive performance difficulty and sleep disturbances. No correlations were found between the performance on the Working memory domain and wellbeing. Future research should focus on unravelling the underlying mechanisms of neurocognitive dysfunction further using neuropsychological tests, including a symptom validity test in combination with neuroimaging techniques in larger samples.
Collapse
Affiliation(s)
- M A M Janssen
- Department of Medical Psychology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
| | | | | | | | | |
Collapse
|
9
|
la Porte C, Verweij-van Wissen C, van Ewijk N, Aarnoutse R, Koopmans P, Reiss P, Stek M, Hekster Y, Burger D. Pharmacokinetic Interaction Study of Indinavir/Ritonavir and the Enteric-Coated Capsule Formulation of Didanosine in Healthy Volunteers. J Clin Pharmacol 2013; 45:211-8. [PMID: 15647414 DOI: 10.1177/0091270004271063] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Didanosine enteric-coated should be taken on an empty stomach, but the once-daily combination of indinavir/ritonavir can be taken with food. Because these drugs are frequently included in 1 regimen, the food effects on the pharmacokinetics were evaluated. This was a randomized, 4-way crossover study of single doses of didanosine enteric-coated 400 mg and indinavir/ritonavir 1200/400 mg in 8 healthy subjects. The following regimens were given: didanosine enteric-coated 2 hours after breakfast (reference regimen A), indinavir/ritonavir with breakfast (reference regimen B), didanosine enteric-coated + indinavir/ritonavir 2 hours after breakfast (test regimen C), and didanosine enteric-coated + indinavir/ritonavir with breakfast (test regimen D). Breakfast was 550 kcal, 28% fat. Blood samples were drawn before and up to 24 hours after ingestion. Statistical comparisons of test regimens C and D with reference regimens A and B were made using the equivalence approach for indinavir and didanosine area under the curve and C(max) (0.80-1.25). Eight subjects (5 men, 3 women) were enrolled and completed the study. Indinavir area under the curves were bioequivalent in test regimens C and D compared to reference regimen B. A 14% increased C(max) was observed in test regimen C. Didanosine area under the curve in test regimen D was 4% lower and suggestive of bioequivalence compared to reference regimen A. However, test regimen C didanosine area under the curve was 23% lower and bioinequivalent compared to reference regimen A. Didanosine C(max) decreased 42% and 46% in test regimens C and D, respectively, in comparison to reference regimen A. In this study, dosing didanosine enteric-coated 400 mg once daily + indinavir/ritonavir 1200/400 mg once daily with breakfast indicated no decrease in the amount of absorption for either didanosine and indinavir and that this regimen could be administered with food.
Collapse
Affiliation(s)
- C la Porte
- Department of Clinical Pharmacy, University Medical Centre Nijmegen, PO Box 9101, 533 KF, 6500 HB, Nijmegen, the Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Koopmans PP, Ellis R, Best BM, Letendre S. Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med 2009; 67:206-211. [PMID: 19749389 PMCID: PMC5077299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The continuous replication of HIV-1 in the central nervous system, in particular the brain, and its potential long-term deleterious effect is the focus of this review. Cognitive deficits are observed in a significant percentage of HIV-1-infected patients. That may occur despite successful peripheral suppression of the HIV-1 replication. Compartmentalisation of HIV-1 in the brain, genetic mutation of HIV-1, age, HCV coinfection and poor intracerebral penetration, as well as possibly a direct toxic effect of antiretroviral drugs, are factors that may account for potential creeping damage of the brain after many years of treatment. Patients with neurological symptoms or cognitive deficits may require another approach to the treatment of their HIV infection.
Collapse
Affiliation(s)
- P P Koopmans
- Department of General Internal Medicine, Radboud University Medical Center Nijmegen, The Netherlands.
| | | | | | | |
Collapse
|
11
|
van den Bout-van den Beukel CJP, van den Bos M, Oyen WJG, Hermus ARMM, Sweep FCGJ, Tack CJJ, Bosch MEW, Burger DM, Koopmans PP, van der Ven AJAM. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med 2008; 9:771-9. [DOI: 10.1111/j.1468-1293.2008.00630.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Burger DM, Huisman A, Van Ewijk N, Neisingh H, Van Uden P, Rongen GA, Koopmans P, Bertz RJ. The Effect of Atazanavir and Atazanavir/Ritonavir on UDP-Glucuronosyltransferase Using Lamotrigine as a Phenotypic Probe. Clin Pharmacol Ther 2008; 84:698-703. [DOI: 10.1038/clpt.2008.106] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
13
|
van Laarhoven HWM, Blokx WA, Seyger MMB, Koopmans PP. A patient with abdominal pain and a rash. Neth J Med 2008; 66:48-49. [PMID: 18219072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Affiliation(s)
- H W M van Laarhoven
- Department of Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
| | | | | | | |
Collapse
|
14
|
Sprenger HG, ten Napel CHH, Vriesendorp R, Hoepelman IM, Legrand JC, Koopmans PP, Kasteren ME, Bravenboer B, ten Kate RW, Groeneveld PHP, Werf TS, Gisolf EH, Richter C. FREE trial: induction therapy with ART (abacavir/lamivudine/lopinavir/r) followed by maintenance regimen with triple NRTI, compared to continued ART. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
15
|
Cleijsen RMM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, de Wolf F, Burger DM. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 2007; 60:897-900. [PMID: 17704117 DOI: 10.1093/jac/dkm298] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Therapeutic drug monitoring (TDM) is being applied for a number of antiretroviral agents. Little is known about the use of TDM for atazanavir. METHODS This is a retrospective cohort analysis on the use of TDM of atazanavir at three clinical sites in The Netherlands. Patients were divided into three groups: (i) all patients with evaluable data of plasma atazanavir concentrations and its relationship with hyperbilirubinaemia; (ii) patients who started atazanavir without documented evidence of protease inhibitor (PI) mutations; (iii) patients who started atazanavir with documented evidence of PI mutations. The genotypic inhibitory quotient (GIQ) was calculated by dividing the mean atazanavir plasma trough concentration by the number of PI mutations. RESULTS A total of 108 patients were included; 70 (65.8%) were using atazanavir/ritonavir (300/100 mg once daily). No significant relationship was observed between atazanavir plasma trough concentration and antiviral response in patients starting atazanavir without PI mutations (group 2; n = 82). In contrast, a significant relationship was observed between atazanavir GIQ and treatment response in patients starting atazanavir while having PI mutations (group 3; n = 26). The cut-off value for GIQ most predictive of virological failure was 0.23 mg/L/mutation: patients (n = 8) with a GIQ equal to or below this value had 50% virological failure whereas patients (n = 18) with a GIQ above 0.23 mg/L/mutation had only 11% virological failure (chi(2): P = 0.030). Atazanavir plasma trough concentrations were significantly related with the occurrence of increased total bilirubin concentrations. CONCLUSIONS TDM of atazanavir might be beneficial for patients with documented PI resistance or patients with hyperbilirubinaemia.
Collapse
Affiliation(s)
- R M M Cleijsen
- Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
16
|
la Porte CJL, de Graaff-Teulen MJA, Colbers EPH, Voncken DS, Ibanez SM, Koopmans PP, Hekster YA, Burger DM. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. Br J Clin Pharmacol 2005; 58:632-40. [PMID: 15563361 DOI: 10.1111/j.1365-2125.2004.02214.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
AIMS A once-daily (q.d.) nucleoside-sparing regimen can prevent mitochondrial toxicity, overcome viral resistance and improve compliance. In the present study the effect of efavirenz on the pharmacokinetics and tolerability of once-daily nelfinavir/ritonavir was evaluated in healthy subjects. METHODS This was a multiple-dose, open-label, single-group, two-period study in 24 healthy subjects. Each received from days 1-10 (period 1): 1875 mg nelfinavir plus 200 mg ritonavir q.d. with a 300-kcal snack. During days 11-20 (period 2) efavirenz 600 mg q.d. was added to the regimen. Blood samples were collected up to 24 h after dosing on days 10 (period 1) and 20 (period 2). High-performance liquid chromatography methods were used for the determination of the concentrations of all compounds. The main pharmacokinetic parameters were calculated using noncompartmental methods. RESULTS All subjects completed the study. After the first period mean nelfinavir AUC(0-24 h), C(max) and C(24) were 49.6 mg h(-1) l(-1), 5.0 mg l(-1) and 0.37 mg l(-1), and the sum of nelfinavir plus its active metabolite M8 C(24) was 0.83 mg l(-1). The relative bioavailability, expressed as a geometric mean ratio (90% confidence interval) for nelfinavir AUC(0-24 h), C(max) and C(24) of period 2 compared with period 1 was: 1.30 (1.21, 1.40), 1.29 (1.19, 1.40) and 1.48 (1.32, 1.66). The sum of nelfinavir and M8 C(24) in period 2 was 0.99 mg l(-1), an increase of 19%. No serious adverse events occurred. CONCLUSIONS The studied regimens were well tolerated. Nelfinavir/ritonavir given together with efavirenz resulted in a 48% higher mean C(24) concentration for nelfinavir, and the sum of nelfinavir and M8 C(24) concentrations was 0.99 mg l(-1). Efavirenz exposure in this study was similar to that reported previously, and therefore can be used effectively in combination with ritonavir and nelfinavir.
Collapse
Affiliation(s)
- C J L la Porte
- Department of Clinical Pharmacy, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Burger DM, van der Ven AJAM, Koopmans PP. Highly active antiretroviral therapy for HIV infection: lessons for the future. Neth J Med 2004; 62:407-8. [PMID: 15685891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
HIV-related morbidity and mortality has been greatly reduced since the introduction of highly active antiretroviral therapy. Issues regarding the patient, the virus, the drugs and the treatment team are discussed. HIV treatment remains complex with a rapidly changing field of possibilities and views, and should therefore be limited to specialised centres.
Collapse
|
18
|
Stokman MA, Wachters FM, Koopmans P, Burgerhof JGM, Groen HJM, Spijkervet FKL, Uges DRA, Hospers GAP. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Res 2004; 24:3263-7. [PMID: 15510621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
BACKGROUND Intravenous administration of amifostine reduces chemotherapy-induced toxicity. Preclinical experiments showed a reduction in radiation-induced mucositis after local application of the active metabolite of amifostine (WR-1065). This study evaluated the effect of local application of WR-1065 on chemotherapy-induced oral mucositis. PATIENTS AND METHODS Non-small cell lung cancer patients treated with gemcitabine and epirubicin every 3 weeks for a maximum of five cycles were included. WR-1065 was administered during the second and third cycle as an oral rinse. Oral mucositis evaluation included WHO toxicity grading, a validated oral mucositis assessment scale (OMAS) and a questionnaire. RESULTS Twenty-four patients were evaluated for at least one control and one rinse cycle. Mucositis scores, pain and feeding difficulties increased from day 1 to day 15, and were not significantly different between the control and rinse cycles. Local application of WR-1065 leads to detectable quantities of WR-1065 in epithelial mucosa cells. A negative correlation between the WR-1065 concentration and OMAS score was found. CONCLUSION No clinical detectable influence of WR-1065 on oral mucositis was found.
Collapse
Affiliation(s)
- M A Stokman
- Department of Oral and Maxillofacial Surgery, University Hospital Groningen, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
la Porte CJL, Colbers EPH, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-60. [PMID: 15105105 PMCID: PMC400571 DOI: 10.1128/aac.48.5.1553-1560.2004] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In the present study, two adjusted-dose regimens of lopinavir-ritonavir were tested in combination with rifampin. Thirty-two healthy subjects participated in a randomized, two-arm, open-label, multiple-dose, within-subject controlled study. All subjects were treated with lopinavir-ritonavir at 400/100 mg BID from days 1 to 15. From days 16 to 24, the subjects in arm 1 received lopinavir-ritonavir at 800/200 mg BID in a dose titration, and the subjects in arm 2 received lopinavir-ritonavir at 400/400 mg BID in a dose titration. Rifampin was given at 600 mg once daily to all subjects from days 11 to 24. The multiple-dose pharmacokinetics of lopinavir, ritonavir, and rifampin were assessed. Twelve of 32 subjects withdrew from the study. For nine subjects lopinavir-ritonavir combined with rifampin resulted in liver enzyme level elevations. Pharmacokinetic data for 19 subjects were evaluable. Geometric mean ratios for the lopinavir minimum concentration in serum and the maximum concentration in serum (C(max)) on day 24 versus that on day 10 were 0.43 (90% confidence interval [CI], 0.19 to 0.96) and 1.02 (90% CI, 0.85 to 1.23), respectively, for arm 1 (n = 10) and 1.03 (90% CI, 0.68 to 1.56) and 0.93 (90% CI, 0.81 to 1.07), respectively, for arm 2 (n = 9). Ritonavir exposure increased from days 10 to 24 in both arms. The geometric mean C(max) of rifampin was 13.5 mg/liter (day 24) and was similar between the two arms. Adjusted-dose regimens of lopinavir-ritonavir in combination with therapeutic drug monitoring and monitoring of liver function may allow concomitant use of rifampin.
Collapse
Affiliation(s)
- C J L la Porte
- Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
McCall MBB, van Lith-Verhoeven JJC, van Crevel R, Crama N, Koopmans PP, Hoyng CB, van der Ven AJAM. Ocular syphilis acquired through oral sex in two HIV-infected patients. Neth J Med 2004; 62:206-8. [PMID: 15460502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Two cases of ocular syphilis are described in HIV-infected individuals after unprotected oral sex. The primary syphilitic lesion remained unnoticed and lues was therefore only diagnosed after visual symptoms developed.
Collapse
Affiliation(s)
- M B B McCall
- Department of (General) Internal Medicine, University Medical Centre St Radboud, Nijmegen, the Netherlands
| | | | | | | | | | | | | |
Collapse
|
21
|
ter Hofstede HJM, Burger DM, Koopmans PP. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. Neth J Med 2003; 61:393-403. [PMID: 15025414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- H J M ter Hofstede
- Department of Internal Medicine, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
| | | | | |
Collapse
|
22
|
Koopmans PP. [Enfuvirtide, the first representative of a new class of drugs for the treatment of HIV infection : HIV fusion inhibitors]. Ned Tijdschr Geneeskd 2003; 147:1726-9. [PMID: 14520797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
In March 2003, enfuvirtide was approved in the USA and the European Union for the treatment of patients with HIV infection who have experienced failure or intolerable side effects of treatment with at least one representative of each antiretroviral drug class. Enfuvirtide has a new mode of action: it binds to the viral envelope glycoprotein 41 that is involved in the fusion of the virus to the membrane of the CD4 T cell. In two large phase III studies, 90 mg of enfuvirtide administered twice daily subcutaneously in addition to a background treatment of other antiretroviral drugs, had a significant favourable effect on both the plasma viral load (decrease) and the CD4 counts (increase) compared to the background treatment alone. Disadvantages of treatment with enfuvirtide are its subcutaneous administration (98% of the patients had local adverse reactions) and the high costs involved (1500 euro per patient per month).
Collapse
Affiliation(s)
- P P Koopmans
- Universitair Medisch Centrum St Radboud, afd. Algemene Interne Geneeskunde, Postbus 9101, 6500 HB Nijmegen.
| |
Collapse
|
23
|
Frost BM, Lönnerholm G, Koopmans P, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Uges DRA, de Graaf SSN. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 2003; 92:551-7. [PMID: 12839283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
AIM To investigate whether there is any pharmacokinetic rationale for the common practice of administering vincristine to adolescents at relatively lower doses than those to younger children. METHODS A total of 98 children, aged 1.3-17.3 y, with acute lymphoblastic leukaemia (ALL) were studied on day 1 of induction therapy. Plasma samples were drawn before and 10, 30, 360 and 1380 min after injection of vincristine 2.0 mg/m2 (maximum dose 2.0 mg) and analysed by high-performance liquid chromatography. RESULTS The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553). No correlation was found between age and any of these pharmacokinetic parameters. The area under the concentration time curve (AUC) was significantly correlated to age (p = 0.002; p - 0.31), as expected from the dosage of vincristine. The lower AUC in children with a body surface area > 1 m2, which is reached at 8-9 y of age, indicates that they received a less intense treatment because of the capping of the vincristine dose at 2.0 mg. CONCLUSIONS Vincristine pharmacokinetics were not age dependent in this paediatric population. Thus, we found no pharmacokinetic rationale for dose reduction in adolescents. The common practice of limiting the vincristine dose to 2.0 mg should be carefully reconsidered.
Collapse
Affiliation(s)
- B M Frost
- Department of Women's and Children's Health, University Children's Hospital, Uppsala, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
van Oosterhout JJG, Boeree MJ, Burger DM, de Lange WCM, van Crevel R, Koopmans PP. [Tuberculosis and HIV coinfection in three patients: the possibilities for simultaneous treatment]. Ned Tijdschr Geneeskd 2003; 147:369-72. [PMID: 12661452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
Three patients received simultaneous treatment for tuberculosis and HIV: a 23-year-old woman and a 33-year-old man who were asylum seekers from Africa and a 45-year-old woman who was an intravenous drug addict. During the treatment with antiretroviral and anti-tuberculous drugs, several problems arose: drug interactions (between rifampicine and protease inhibitors/non-nucleoside reverse transcriptase inhibitors), side effects, non-compliance and immune reconstitution reactions. These problems were solved either by temporary withdrawal of the medication or by substituting other drugs. There are a number of possible treatment strategies that minimise the risks. Despite the potential problems, in patients with advanced HIV infection, antiretroviral treatment should not be delayed until after the end of the tuberculosis treatment.
Collapse
Affiliation(s)
- J J G van Oosterhout
- Afd. Algemene Interne Geneeskunde, Universitair Medisch Centrum St Radboud, Postbus 9101, 6500 HB Nijmegen
| | | | | | | | | | | |
Collapse
|
25
|
Aarnoutse RE, Droste JAH, van Oosterhout JJG, Koopmans PP, Popescu M, Reiss P, Hekster YA, Burger DM. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol 2003; 55:115-25. [PMID: 12580982 PMCID: PMC1894733 DOI: 10.1046/j.1365-2125.2003.01756.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
AIMS This study was performed to evaluate the steady-state pharmacokinetics, food intake requirements and short-term tolerability of once-daily combinations of nelfinavir and low-dose ritonavir. METHODS Twenty-seven healthy volunteers were randomized over three groups to receive a once-daily regimen of nelfinavir/ritonavir 2,000/200 mg (group 1), 2,000/400 mg (group 2) or 2,500/200 mg (group 3) with food for 14 days. Pharmacokinetic parameters for nelfinavir and its active metabolite M8 were assessed on study days 15 and 16, after administration of the regimens with a full (610 kcal) or light (271 kcal) breakfast, respectively. RESULTS Pharmacokinetic data were evaluable for eight volunteers in group 1, eight in group 2 and four in group 3. Administration of nelfinavir/ritonavir with a full breakfast resulted in geometric mean (GM) nelfinavir AUC(24h) values of 76.8, 51.3, and 61.9 h*mg/l in group 1, 2 and 3, respectively. GM 24-h Cmin concentrations of nelfinavir were 0.76 mg l(-1), 0.43 mg l(-1) and 0.47 mg l(-1), respectively. Co-administration of ritonavir increased M8 concentrations more than nelfinavir concentrations, resulting in GM AUC(24h) and Cmin values for nelfinavir plus M8 that were higher than or comparable to reference values for the approved regimen of nelfinavir (1,250 mg BID without ritonavir). In the 2,000/200 mg group, seven out of eight subjects had a Cmin value of nelfinavir plus M8 above a threshold of 1.0 mg l-1. Administration of the combinations with a light breakfast resulted in significant decreases in the AUC(24h) and Cmin of nelfinavir and nelfinavir plus M8, compared with intake with a full breakfast. For the Cmin of nelfinavir plus M8, the GM ratio (light/full breakfast) was 0.76 (90% confidence interval 0.67-0.86, participants from all groups combined). Short-term tolerability was satisfactory, apart from a higher than expected incidence of mild rash (12%). CONCLUSIONS Administration of nelfinavir in a once-daily regimen appears feasible. A nelfinavir/ritonavir 2,000/200 mg combination appears appropriate for further evaluation. Once-daily nelfinavir/ritonavir should be taken with a meal containing at least 600 kcal.
Collapse
Affiliation(s)
- R E Aarnoutse
- Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Croockewit AJ, de Boer JE, van Loenhout JWA, Koopmans PP. [Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain]. Ned Tijdschr Geneeskd 2002; 146:1117-20. [PMID: 12092301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Up until now the standard treatment for metastasized colorectal carcinoma has been fluorouracil (5-FU) in combination with folonic acid in low doses administered intravenously, even after the recent registration of a number of new intravenously administered cytostatics, such as irinotecan and oxaliplatin. Meanwhile there are oral alternatives for 5-FU: capecitabine and the combination of tegafur and uracil with folonic acid. In four randomised studies it was shown that these drugs were globally just as effective as the combination of 5-FU with folonic acid (in accordance with the 'Mayo Clinic' scheme). There was no survival advantage for the oral drugs compared to 5-FU with folonic acid. Compared to 5-FU and folonic acid the use of capecitabine or tegafur-uracil-folonic acid was associated with less toxic effects; however, there were differences in the side effects profile between the oral drugs and 5-FU (more hand-foot syndrome for capecitabine and less (symptomatic) leucopenia for tegafur-uracil-folonic acid). An examination of the serious side effects (grade 3 and 4) revealed that the total incidence was generally comparable. These data, together with the ease of oral administration, form the basis for the registration of capecitabine and tegafur-uracil-folonic acid. The definitive place of these drugs in the treatment of metastasized colorectal carcinoma is not yet clear.
Collapse
Affiliation(s)
- A J Croockewit
- Agentschap ten behoeve van het College ter Beoordeling van Geneesmiddelen, afd. Klinische Beoordelingen, Den Haag.
| | | | | | | |
Collapse
|
27
|
Affiliation(s)
- P P Koopmans
- Department General Internal Medicine, University Medical Center St Radboud, Nijmegen, Netherlands.
| |
Collapse
|
28
|
Hugen PWH, Burger DM, Koopmans PP, Stuart JWTC, Kroon FP, van Leusen R, Hekster YA. Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci 2002; 24:83-6. [PMID: 12136744 DOI: 10.1023/a:1016121100568] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND The soft-gel capsule (sgc) of saquinavir has been developed in order to improve the poor oral bioavailability of the original hard-gel capsules. However, in a Dutch study population using saquinavir-sgc plasma levels were lower than expected. We hypothesised that this was caused by differences in the amount of fat in the meals of the study populations. METHODS 8-h steady-state plasma curves after observed ingestion of 1200 mg saquinavir-sgc were recorded, concomitantly with a normal breakfast (600 kcal, 33% fat) on the first day, and a high-fat breakfast (1040 kcal, 54% fat) on the second day. Additionally, a comparison was made between saquinavir hard-gel capsules and saquinavir-sgc with or without grapefruit juice (n = 1). Furthermore, a comparison between saquinavir-sgc and ritonavir + saquinavir-sgc 400/400 mg bid was made (n = 1). RESULTS Although saquinavir exposure was improved by fat, grapefruit juice or ritonavir, exposure to saquinavir for all recorded curves was lower than expected. A large proportion of trough concentrations was below the efficacy threshold. CONCLUSION Intake of squinavir-sgc with high-fat meals or grapefruit juice may improve the pharmacokinetic profile. However, plasma concentrations may then still be lower than expected and insufficient for good antiviral efficacy. Probably the only way to reach adequate saquinavir concentrations is by combining saquinavir with ritonavir.
Collapse
Affiliation(s)
- P W H Hugen
- Department of Clinical Pharmacy, University Medical Centre Nijmegen, 533 Dept. Clinical Pharmacy, 6500 HB Nijmegen, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
29
|
Koopmans P, Gidding CE, de Graaf SS, Uges DR. An automated method for the bioanalysis of vincristine suitable for therapeutic drug monitoring and pharmacokinetic studies in young children. Ther Drug Monit 2001; 23:406-9. [PMID: 11477324 DOI: 10.1097/00007691-200108000-00014] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Pharmacokinetic studies in young children require very sensitive methods using low plasma volumes. Although vincristine has been used as an antineoplastic drug for almost 40 years, data on vincristine pharmacokinetics and pharmacodynamics are scarce, especially in young children. One of the reasons for this is the lack of a specific and sensitive assay suitable for small plasma volumes. Therefore the authors aimed to improve an existing high-performance liquid chromatography (HPLC) assay by changing the solid-phase extraction material and by using a more sensitive and controlled electrochemical detector. An on-line solid-phase extraction was used with a preconcentration column of 10 * 3 mm ID containing octadecyl silane (ODS) reversed-phase material and an analytical microsphere C18 column. The mobile phase was unchanged and consisted of 35% phosphate buffer 0.02 mol (pH 7.00 +/- 0.10), 50% methanol, and 15% acetonitrile. Detection was performed with a new electrochemical detector. This detector comprised a highly stable Faraday-shielded oven compartment that accommodated a column and flowcell. The flowcell had a spacer thickness of 0.25 microm set at 830 mV. It also had an excellent signal-to-noise ratio, which resulted in very sensitive electrochemical analysis. These improvements resulted in a lower required sample volume of only 0.3 mL instead of 1.2 mL plasma with a very low limit of quantitation of 0.483 microg/L according to good laboratory practice (GLP) rules. The intraday coefficients of variation were 6.2% (0.483 microg/L) and 4.2% (18.4 microg/L). The interday coefficients of variation were 10.3% (0.483 microg/L) and 8.5% (18.4 microg/L).
Collapse
Affiliation(s)
- P Koopmans
- Laboratory for Drug Analysis and Toxicology, Department of Pharmacy, Children's Cancer Center, Beatrix Children's Hospital, University Hospital Groningen, The Netherlands.
| | | | | | | |
Collapse
|
30
|
Koks CH, Crommentuyn KM, Hoetelmans RM, Burger DM, Koopmans PP, Mathôt RA, Mulder JW, Meenhorst PL, Beijnen JH. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001; 51:631-5. [PMID: 11422025 PMCID: PMC2014488 DOI: 10.1046/j.0306-5251.2001.01409.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AIMS To study the effect of fluconazole on the steady-state pharmacokinetics of the protease inhibitors ritonavir and saquinavir in HIV-1-infected patients. METHODS Five subjects treated with saquinavir and three with ritonavir received the protease inhibitor alone (saquinavir 1200 mg three times daily, ritonavir 600 mg twice daily) on day 1, and the same protease inhibitor in combination with fluconazole (400 mg on day 2 and 200 mg on days 3 to 8). Pharmacokinetic parameters were determined on days 1 and 8. RESULTS In the saquinavir group, the median increase in the area under the plasma concentration vs time curve was 50% from 1800 microg l(-1) h to 2700 microg l(-1) h (P = 0.04, median increase: 900 microg l(-1) h; 2.5 and 97.5 percentile: 500-1300), and 56% for the peak concentration in plasma (from 550 to 870 microg l(-1), P = 0.04; median increase: 320 microg l(-1) h, 2.5 and 97.5 percentile: 60-450 microg l(-1)). In the ritonavir group, there were no detectable changes in the pharmacokinetic parameters on addition of fluconazole. CONCLUSIONS Because of the favourable safety profile of saquinavir, dose adjustments are probably not necessary with concomitant use of fluconazole, as is the case for ritonavir.
Collapse
Affiliation(s)
- C H Koks
- Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15:991-8. [PMID: 11399981 DOI: 10.1097/00002030-200105250-00007] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To characterize sources of variation in plasma concentrations of nelfinavir and its active metabolite M8 and to evaluate the use of therapeutic drug monitoring for nelfinavir treatment. METHODS Plasma samples and patient's characteristics were obtained from outpatient clinic. Differences between groups of patients were studied by comparing the observed plasma concentrations with the corresponding concentration on a pharmacokinetic population curve based on median plasma levels. RESULTS Plasma samples (618) were available from 355 patients taking 1250 mg nelfinavir twice daily. The median ratio between M8 and nelfinavir concentrations was 0.29. This ratio appeared to be independent of the time after ingestion. Statistically significantly lower M8 concentrations were found in Black and Asian patients, or when comedication with CYP3A4 inducers was used. Coadministration of CYP2C19 inhibitors, such as omeprazole, decreased the median M8/nelfinavir ratio. Nevertheless, nelfinavir concentrations and summed concentrations of nelfinavir and M8 were only marginally affected in these patients. Diarrhoea was identified as a cause for lower nelfinavir concentrations, without changing the M8/nelfinavir ratio. In a number of patients with suspected therapy failure or intoxication, abnormal nelfinavir plasma concentrations were found. Dose adjustments based on nelfinavir plasma levels were helpful in a number of patients. CONCLUSION This study shows that the total concentration of nelfinavir and M8 together is not significantly influenced when variation in M8 levels occurs. Consequently, measuring M8 concentrations in addition to nelfinavir concentrations is not required for the purpose of therapeutic drug monitoring for this drug.
Collapse
Affiliation(s)
- P A Baede-van Dijk
- Section Clinical Assessments, Medicines Evaluation Board Agency, The Hague, the Netherlands
| | | | | | | | | | | |
Collapse
|
32
|
Croockewit AJ, Koopmans PP, Lekkerkerker JF. [Interferon for adjuvant therapy of melanoma: approved, not indicated]. Ned Tijdschr Geneeskd 2001; 145:498-9. [PMID: 11268915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
33
|
ter Hofstede HJ, Telgt DS, Koopmans PP. [Therapy of HIV infection: how early and how intensive?]. Ned Tijdschr Geneeskd 2001; 145:201-4. [PMID: 11219144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Three men aged 53, 25 and 34 years and 2 women aged 39 and 34 years with HIV infection had different courses with and without highly active antiretroviral therapy (HAART). Medication regimes were often complicated and adverse events occurred frequently, which led to adjustment of treatment. Since the introduction of HAART for treatment of HIV infection, a tremendous progress has been achieved, resulting in reduction of HIV related events and in reduction of fatality due to AIDS. However, besides the positive effects of this therapy, there is also a negative side of HAART. In addition to the complexity and adverse events, the medication has to be taken lifelong while non-compliance might result in resistance-mutation. If HAART might be indicated, it is necessary to weigh the pros and contras before starting with medication.
Collapse
Affiliation(s)
- H J ter Hofstede
- Universitair Medisch Centrum St Radboud, afd. Algemeen Interne Geneeskunde, Postbus 9101, 6500 HB Nijmegen.
| | | | | |
Collapse
|
34
|
Nieuwkerk P, Gisolf E, Sprangers M, Danner S, Gisolf EH, Reiss P, Weverling GJ, Duurvoort M, Krijger E, Brouwer E, Visser GR, Klotz A, Benschop C, Wulfert F, Danner SA, de Wolf F, Jurriaans S, Portegies P, Colebunders R, Pelgrom J, Wijnants H, de Roo A, Keersmaekers K, Vandenbruane M, van den Brande D, James T, van Wanzeele F, van der Gucht B, van der Ende ME, Nouwen J, Deenenkamp R, van der Meyden D, Koopmans PP, Brinkman K, ter Hofstede H, Zomer B, Blok WL, Ruissen C, Sprenger H, Law G, van der Meulen P, ten Veen C, Juttmann JR, van der Heul C, Santegoets R, van der Ven B, Gasthuis K, haarlem, ten Kate RW, Schoemaker M, Kauffmann RH, Henrichs JM, Maat A, Prins E, ten Napel CH, Pogany K, Duyts T, Lansink T, Simons P, Lacor P, de Waele A, van Wijngaarden E, Lejeune M, Scholte R, Dijkman J. Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response. Antivir Ther 2001. [DOI: 10.1177/135965350100600203] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives To investigate adherence to antiretroviral therapy over 48 weeks, to investigate the association between adherence and treatment-related symptoms and to investigate the impact of adherence on virological response over 48 weeks among established predictors of treatment success. Methods One-hundred-and-sixty HIV-1 infected protease inhibitor- and stavudine-naive patients participating in a trial of ritonavir/saquinavir versus ritonavir/saquinavir/ stavudine completed an adherence questionnaire and a symptom checklist at weeks 12, 24, 36 and 48. We calculated odds ratios between experienced symptoms and non-adherence. Regression models were used to determine predictors of HIV-1 RNA below 400 copies/ml at week 48, and of the area about the change from baseline over 48 weeks (ACFB) in serum HIV-1 RNA. Results The percentage of patients reporting missing medication, deviation from time schedule, and dietary prescriptions at separate time-points ranged from 12 to 15%, 32 to 35% and 17 to 22%, respectively. The percentage that changed their level of adherence during 48 weeks ranged from 29% for skipping medication to 48% for deviation from time-schedule. Experienced side-effects were associated with an increased likelihood of non-adherence. Not skipping medication was an independent predictor of both having a serum HIV-1 RNA below 400 copies/ml at week 48 and the ACFB over 48 weeks in serum HIV-1 RNA. Conclusions Adherence was an independent predictor of virological response over 48 weeks. The level of adherence is variable within patients over time. This suggests the need for continued adherence monitoring in all patients as part of standard medical practice.
Collapse
Affiliation(s)
- Pythia Nieuwkerk
- Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Elisabeth Gisolf
- National AIDS Therapy Evaluation Center, Amsterdam, The Netherlands
| | - Mirjam Sprangers
- Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Sven Danner
- National AIDS Therapy Evaluation Center, Amsterdam, The Netherlands
- Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - J Pelgrom
- Institute for Tropical Medicine, Antwerp
| | - H Wijnants
- Institute for Tropical Medicine, Antwerp
| | - A de Roo
- Institute for Tropical Medicine, Antwerp
| | | | | | | | - T James
- Institute for Tropical Medicine, Antwerp
| | | | | | | | | | | | | | | | | | | | - B Zomer
- University Hospital Nijmegen
| | - WL Blok
- Ziekenhuis Walcheren, Vlissingen
| | | | | | - G Law
- University Hospital Groningen
| | | | | | | | | | | | | | | | - haarlem
- St Elisabeth Ziekenhuis Tilburg
| | | | | | | | | | - A Maat
- Ziekenhuis Leyenburg, Den Haag
| | - E Prins
- Ziekenhuis Leyenburg, Den Haag
| | | | - K Pogany
- Medisch Spectrum Twente, Enschede
| | - T Duyts
- Medisch Spectrum Twente, Enschede
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Hugen PW, Burger DM, ter Hofstede HJ, Koopmans PP, Stek M, Hekster YA, Reiss P, Lange JM. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr 2000; 25:236-45. [PMID: 11115954 DOI: 10.1097/00126334-200011010-00005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In antiretroviral therapy, to improve compliance the need is increasing to develop regimens that combine potency and safety with convenient dosing. The objective of our study was to find a once-daily dosing regimen of a HIV-protease inhibitor, indinavir (IDV), by combining it with ritonavir (RTV). In the study, 12 healthy volunteers took a single IDV dose of 800 mg on day 1. Plasma and urine sampling was done for 12 hours. From day 2 to day 21, participants took RTV liquid 200 mg (group A) or 400 mg (group B) once daily. Repeated pharmacokinetic sampling was performed over the course of 24 hours, after single doses of indinavir 400 mg (day 15), 800 mg (day 18), and 1200 mg (day 21). The best dosage regimen in this pharmacokinetic study was selected based on efficacy and tolerability criteria. The study comprised 10 male and 2 female healthy volunteers, mean age, 25 years (range, 18-50 years), mean weight, 70 kg (range, 52-83 kg). One male participant discontinued on day 8 due to influenza. All other participants completed the study without the occurrence of serious adverse events. RTV inhibited indinavir plasma clearance by 51% to 70%, leading to increased and prolonged IDV exposure. Renal clearance was influenced by the addition of RTV and dosage increments of IDV. The efficacy criterion was best fulfilled by 1200 mg IDV/400 mg RTV, whereas this combination performed most poorly on tolerability criteria. Based on the single dose data, a once-daily regimen of IDV with a low dose of RTV is possible. The best dosage regimen to start with among those studied here appears to be 1200 mg IDV/400 mg RTV, which could be decreased at steady state to 800 IDV/400 RTV or 1200 IDV/200 RTV if toxicity occurs. Steady-state pharmacokinetic data of once-daily IDV/RTV regimens in HIV-infected patients are warranted.
Collapse
Affiliation(s)
- P W Hugen
- Department of Clinical Pharmacy; Department of General Internal Medicine, University Medical Centre St. Radboud Nijmegen and National AIDS Therapy Evaluation Centre, Academical Medical Centre, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Hugen PW, Burger DM, de Graaff M, ter Hofstede HJ, Hoetelmans RM, Brinkman K, Meenhorst PL, Mulder JW, Koopmans PP, Hekster YA. Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir. Ther Drug Monit 2000; 22:437-45. [PMID: 10942185 DOI: 10.1097/00007691-200008000-00013] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The presence of the HIV-protease inhibitor indinavir in saliva was analyzed to investigate whether salivary indinavir concentrations are applicable to monitor compliance and/or predict plasma indinavir levels. Fourteen HIV-infected outpatients treated with indinavir and 24 healthy volunteers who ingested a single dose of indinavir were included. Paired plasma and citric-acid-stimulated saliva samples were analyzed by high-performance liquid chromatography (HPLC). Stimulated salivary indinavir concentrations showed a high correlation (r = 0.85, p < 0.01) with corresponding plasma levels. The median saliva/plasma ratio was 65% (P25 50%; P75 94%). The ratios were independent of the plasma concentration; however, a relation with time after ingestion was seen. The unbound fraction of indinavir in plasma was not significantly correlated with the saliva/plasma ratio after stimulated saliva collection, in contrast with a subset of nonstimulated saliva from healthy volunteers, where we did find a significant correlation. Although stimulated salivary indinavir concentrations are highly correlated with plasma concentrations, it is not possible to predict plasma indinavir levels by the salivary concentrations for purposes of therapeutic drug monitoring, due to large interindividual and intraindividual variation. Nevertheless, monitoring compliance by measuring the presence of indinavir in saliva is possible: ingestion of indinavir can be assessed with a sensitivity of 84.8% in the whole dosing interval or with 98.8% between 1 and 6 hours after the last dose, which is comparable with plasma.
Collapse
Affiliation(s)
- P W Hugen
- Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
An indinavir oral liquid was developed and studied. Several oral liquids containing indinavir were prepared and taste tested in eight healthy volunteers. Physical and chemical stability over two weeks were examined, and a randomized, two-way-crossover, single-dose bioequivalence trial was performed in 12 healthy male volunteers. Indinavir 800 mg was given as two 400-mg indinavir capsules (Crixivan) on day 1 and as 80 mL of the indinavir liquid on day 2, or vice versa. A standard breakfast and lunch were given at fixed times, and blood and urine samples were collected at various intervals up to eight hours. The log-transformed area under the concentration-versus-time curve from zero to eight hours (AUC0-8) and maximum plasma concentration (Cmax) for the liquid versus the capsules were compared by using a 90% confidence interval (CI) test (limits, 80-125%), and the time to Cmax (tmax) was compared by using the nonparametric sign test. The liquid selected had an acceptable taste, contained indinavir 10 mg/mL, and was chemically stable for two weeks at 4 degrees C. The 90% CI for the AUC ratio (liquid versus capsules) was 92-99% (mean, 95%); for the Cmax ratio it was 95-106% (mean, 100%). There was no significant difference in tmax between the liquid and capsules. An oral liquid formulation of indinavir was developed that had an acceptable taste, was chemically stable, and was bioequivalent to the commercially available capsule.
Collapse
Affiliation(s)
- P W Hugen
- Department of Clinical Pharmacy, Faculty of Medicine, University Hospital Nijmegen, Netherlands.
| | | | | | | | | |
Collapse
|
39
|
Hollanders RM, van Ewijk-Beneken Kolmer EW, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744:65-71. [PMID: 10985567 DOI: 10.1016/s0378-4347(00)00231-0] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A sensitive and rapid high-performance liquid chromatography method has been developed to measure the levels of the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine in human plasma. The sample pre-treatment consists of a protein precipitation with perchloric acid. A Hypersil ODS column is used at ambient temperature and a wavelength of 280 nm is used for ultraviolet detection. The mobile phase contains acetonitrile and a 60 mM phosphate buffer pH 4.5 (30:70, v/v). The detection limit of the method is 0.05 mg/l using 150 microl of plasma. The lower and upper limit of quantitation are 0.1 mg/l and 10 mg/l, respectively. The average recovery of nevirapine is 101.8% with a variation of 4.6%. The average inter-assay precision is 2.4%, the average intra-assay precision 2.9% and the average accuracy 97%.
Collapse
Affiliation(s)
- R M Hollanders
- Department of Clinical Pharmacy, 533 KF University Medical Center, Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|
40
|
Koopmans PP, de Graeff PA, van Zwieten-Boot BJ, Lekkerkerker JF, Broekmans AW. [Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and patient?]. Ned Tijdschr Geneeskd 2000; 144:756-61. [PMID: 10812445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The clinical criteria for admission of new drugs to the European common market have become more stringent in recent years. Increasingly often, the manufacturer is required to demonstrate that the new drug offers a clinically visible and relevant benefit to the patient. Efficacy and adverse effects should not only be studied by comparative trials with placebo, the registration authorities also expect the drug to be compared with the standard treatment already available. Such trials should prove that the balance between efficacy and adverse effects of the drug is better than that of placebo and at least as good as the standard treatment, as regards not only statistical significance but also clinical relevance. Therefore, Dutch and European assessment reports and product information may be increasingly useful to prescribers, patients and insurers in determining the role and therapeutic value of new drugs within the existing therapeutic possibilities concerning certain diseases.
Collapse
Affiliation(s)
- P P Koopmans
- College ter beoordeling van geneesmiddelen, afd. Klinische Beoordelingen Agentschap, Den Haag
| | | | | | | | | |
Collapse
|
41
|
Hugen PW, Burger DM, Brinkman K, ter Hofstede HJ, Schuurman R, Koopmans PP, Hekster YA. Carbamazepine--indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000; 34:465-70. [PMID: 10772431 DOI: 10.1345/aph.19211] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE To report a case of antiretroviral therapy failure caused by an interaction between carbamazepine and indinavir. CASE SUMMARY A 48-year-old HIV-positive white man was treated with antiretroviral triple therapy, consisting of indinavir, zidovudine, and lamivudine. His HIV-RNA (viral load) became undetectable (<400 copies/mL) less than two months after this therapy was started; this was confirmed one month later. Shortly after the start of antiretroviral therapy, the patient developed herpes zoster, which was treated with famciclovir. Tramadol was initially prescribed for postherpetic neuralgia; however, this was substituted with carbamazepine due to insufficient analgesic effect. Indinavir plasma concentrations decreased substantially during carbamazepine therapy. Carbamazepine was stopped after 2.5 months and, two weeks later, the HIV-RNA was detectable (6 x 103 copies/mL). Resistance for lamivudine was observed in that blood sample; resistance for zidovudine might have been present, and resistance to indinavir was not detected. A few months later, a further increase of the HIV-RNA occurred (300 x 103 copies/mL), after which the therapy was switched to a new antiretroviral regimen containing nevirapine, didanosine, and stavudine. DISCUSSION Physicians may prescribe carbamazepine for HIV-infected patients to treat seizures or postherpetic neuralgia, which are complications of opportunistic infections such as herpes zoster or toxoplasmosis. Carbamazepine is a potent enzyme inducer, predominantly of the CYP3A enzyme system, while HIV-protease inhibitors such as indinavir are substrates for and inhibitors of CYP3A. Therefore, an interaction between these drugs could be expected. A low dose of carbamazepine (200 mg/d) and the usual dose of indinavir (800 mg q8h) in our patient resulted in carbamazepine concentrations within the therapeutic range for epilepsy treatment; indinavir concentrations dropped substantially. The virologic, resistance, and plasma drug concentration data, as well as the chronology of events, are highly indicative of antiretroviral treatment failure due to the interaction between carbamazepine and indinavir. CONCLUSIONS Concomitant use of carbamazepine and indinavir may cause failure of antiretroviral therapy due to insufficient indinavir plasma concentrations. Drugs other than carbamazepine should be considered to prevent this interaction. Amitriptyline or gabapentin are alternatives for postherpetic neuralgia; valproic acid or lamotrigine are alternatives for seizures. When alternate drug therapy is not possible, dosage adjustments, therapeutic drug monitoring, and careful clinical observation may help reduce adverse clinical consequences.
Collapse
Affiliation(s)
- P W Hugen
- Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
42
|
Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 2000; 3:215-20. [PMID: 10682141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
All human immunodeficiency virus type 1 (HIV-1)-infected patients who started to use indinavir (800 mg three times a day) as part of their triple drug regimen were included in a study to determine the importance of low plasma concentrations of indinavir as a cause of virological treatment failure. The indinavir concentration and a number of patient characteristics at baseline were tested as risk factors for virological treatment failure (defined as a viral load above 200 copies/ml after 24 weeks of treatment) in univariate and multivariate analyses; 65 patients were included. Virological treatment failure occurred in 36.9% of the patients. Multivariate analysis showed that a low plasma concentration of indinavir (odds ratio 0.1), a high viral load at baseline (odds ratio 2.6) and pretreatment with another protease inhibitor (odds ratio 10.0) were independent factors related to virological treatment failure. Monitoring of indinavir plasma concentrations may be an important tool for the optimization of triple drug combination therapy.
Collapse
Affiliation(s)
- D M Burger
- Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
van Loon FP, Voordouw AC, Simonian S, Koopmans PP. [Critical review of anti-influenza drugs]. Ned Tijdschr Geneeskd 2000; 144:165-7. [PMID: 10668542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Neuraminidase inhibitors such as zanamivir and oseltamivir belong to a new class of antiviral drugs for the treatment and prevention of influenza. As yet however, the therapeutic efficacy of these drugs (shortening of recovery time by approximately one day) has only been demonstrated in healthy adults affected by influenza A, but not in risk groups and in influenza B disease, whereas studies of prophylactic efficacy are still going on. Neither do these drugs impact on viral spread, a public health risk against which the economic advantages of early work resumption have to be weighed. Since flu symptoms can be caused by other germs than the influenza A or B virus, caution in prescribing these drugs seems warranted, also to prevent the development of drug resistance. In addition, when designing therapeutic efficacy trials in risk groups, selecting the rate of secondary complications and death may be more adequate as clinical endpoint than (economically important) duration of illness.
Collapse
Affiliation(s)
- F P van Loon
- College ter beoordeling van geneesmiddelen, Den Haag.
| | | | | | | |
Collapse
|
44
|
Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999; 44:203-9. [PMID: 10453721 DOI: 10.1007/s002800050968] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE We studied vincristine disposition after 169 weekly i.v. bolus injections in 32 children with acute lymphoblastic leukemia, non-Hodgkin lymphoma, or Wilms' tumor. The aim of the study was to determine intrapatient and interpatient variability in vincristine disposition and demographic, clinical, and biochemical characteristics influencing this variability. METHODS Vincristine plasma concentrations were measured by a high-performance liquid chromatography assay with electrochemical detection. A limited sampling strategy was used based on a bayesian parameter estimation algorithm that is part of the ADAPT II software package. A two-compartment, first-order model was fitted to the data, and pharmacokinetic parameters were calculated from the model using the ADAPT II software. For statistical analysis, analysis of variance (ANOVA), t test, simple and multiple regression analysis, and non-parametric or robust equivalents were used. RESULTS Results showed a large intrapatient and interpatient variability in distribution half-life, elimination half-life, total body clearance, apparent volume of distribution at steady state, and area under the concentration-time curve. Intrapatient variability was significantly smaller than interpatient variability for all these parameters except distribution half-life. The diagnosis or treatment protocol turned out to be the most predictive characteristic; leukemia and non-Hodgkin lymphoma patients had a significantly higher total body clearance than Wilms' tumor patients. CONCLUSIONS We conclude that both intrapatient and interpatient variability in vincristine pharmacokinetics is large in pediatric cancer patients and that variability, although significantly influenced by diagnosis, largely remains unpredictable.
Collapse
Affiliation(s)
- C E Gidding
- Children's Cancer Center, University Hospital Groningen, The Netherlands
| | | | | | | | | | | |
Collapse
|
45
|
Cohen Stuart JW, Schuurman R, Burger DM, Koopmans PP, Sprenger HG, Juttmann JR, Richter C, Meenhorst PL, Hoetelmans RM, Kroon FP, Bravenboer B, Hamann D, Boucher CA, Borleffs JC. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 1999; 13:F53-8. [PMID: 10357371 DOI: 10.1097/00002030-199905070-00001] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To compare efficacy and tolerability of saquinavir soft gelatin capsule (SQV-SGC) formulation and indinavir, both given as part of a triple drug regimen containing zidovudine and lamivudine, in HIV-1-infected individuals. DESIGN Randomized, open label, multicentre study. PATIENTS A total of 70 patients who were antiretroviral-naive and who had a CD4 cell count < 500 x 10(6)/I and/or > 10000 HIV RNA copies/ml plasma and/or HIV-related symptoms. Subjects were assigned randomly to zidovudine 200 mg three times per day plus lamivudine 150 mg twice per day plus either SQV-SGC 1200 mg three times per day (SQV-SGC group) or indinavir 800 mg three times per day (indinavir group). Data are presented for all patients up to week 24. RESULTS Mean baseline CD4 cell counts (+/- SE) were 301+/-29 x 10(6) cells/l and 310 +/-43 x 10(6) cells/l in the SQV-SGC and indinavir groups, respectively. The log10 median baseline HIV RNA load was 5.00 copies/ml in the SQV-SGC group and 4.98 copies/ml in the indinavir group. No difference in antiretroviral effect between the treatment arms could be demonstrated. Intention-to-treat analysis (last observation carried forward [LOCF]) at week 24 revealed that RNA levels decreased to < 50 copies/ml in 74.3% of patients in the SQV-SGC group and in 71.4% of the patients in the indinavir group (P = 0.78). In the on-treatment analysis the proportion of patients < 50 copies/ml at week 24 was 88.0% in the SQV-SGC group and 84.6% in the indinavir group (P = 0.725). Intriguingly, the mean increase of CD4 cells in the first 24 weeks was 162+/-20 x 10(6) cells/l in the SQV-SGC group and 89+/-21 x 10(6) cells/l in the indinavir group (P = 0.01), but preliminary data indicate that this difference in CD4 cell count gain may disappear after 24 weeks of treatment. Both regimens were generally well tolerated. CONCLUSION During the first 24 weeks of the study, we found no difference in antiviral potency between the indinavir group and the SQV-SGC group. A significantly higher CD4 response in the SQV-SGC group was observed.
Collapse
Affiliation(s)
- J W Cohen Stuart
- Department of Internal Medicine, University Hospital Utrecht, Eijkman Winkler Institute, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
ter Hofstede HJ, van der Ven AJ, Koopmans PP. Drug reactions to contrimoxazole in HIV infection: possibly not due to the hydroxylamine metabolites of sulphamethoxazole. Br J Clin Pharmacol 1999; 47:571-3. [PMID: 10400465 PMCID: PMC2014187 DOI: 10.1046/j.1365-2125.1999.00925.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 727:139-49. [PMID: 10360433 DOI: 10.1016/s0378-4347(99)00079-1] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A sensitive high-performance liquid chromatographic method has been developed for the simultaneous determination of the four licensed HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir. An aliquot of 500 microl plasma, spiked with internal standard, was extracted with 0.5 ml 0.1 M NH4OH and 5 ml methyl tert.-butyl ether. After evaporating, the residue was dissolved in eluent consisting of acetonitrile-50 mM phosphate buffer, pH 5.63 (40:60, v/v). Subsequently, the eluent was washed with hexane. Chromatography was performed using a C18 reversed-phase column and gradient elution with a linear increase of acetonitrile from 36 to 66%. Ultraviolet detection at 215 nm was used. Linearity of the method was obtained in the concentration range of 45-30 000 ng/ml for all four analytes. The method was validated extensively and stability tests under various conditions were performed. The assay is now in use to analyse plasma samples from patients treated with (combinations of) HIV-protease inhibitors.
Collapse
Affiliation(s)
- P W Hugen
- Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands.
| | | | | | | | | | | |
Collapse
|
48
|
Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, van der Ende ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999; 13:203-12. [PMID: 10202826 DOI: 10.1097/00002030-199902040-00008] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Current antiretroviral treatment can induce significant and sustained virological and immunological responses in HIV-1-infected persons over at least the short- to mid-term. OBJECTIVES In this study, long-term immune reconstitution was investigated during highly active antiretroviral therapy. METHODS Patients enrolled in the INCAS study in The Netherlands were treated for 102 weeks (range 52-144 weeks) with nevirapine (NVP) + zidovudine (ZDV) (n = 9), didanosine (ddl) + ZDV (n = 10), or NVP + ddl + ZDV (n = 10). Memory and naïve CD4+ and CD8+ T cells were measured using CD45RA and CD27 monoclonal antibodies (mAb), T-cell function was assayed by CD3 + CD28 mAb stimulation, and plasma HIV-1 RNA load was measured by ultra-direct assay (cut-off < 20 copies/ml). RESULTS Compared to both double combination regimens the triple combination regimen resulted in the most sustained increase in CD4+ T cells (change in CD4+, + 253 x 10(6) cells/l; standard error, 79 x 10(6) cells/l) and reduction of plasma HIV-1 RNA. In nine patients (31%) (ddl + ZDV, n = 2; NVP + ddl + ZDV, n = 7) plasma HIV-1 RNA levels remained below cut-off for at least 2 years. On average, these long-term virological responders demonstrated a significantly higher increase of naïve and memory CD4+ T cells (P = 0.01 and 0.02, respectively) as compared with patients with a virological failure, and showed improved T-cell function and normalization of the naïve; memory CD8+ T-cell ratio. However, individual virological success or failure did not predict the degree of immunological response. T-cell patterns were independent of baseline CD4+ T-cell count, T-cell function, HIV-1 RNA load or age. Low numbers of naïve CD4+ T cells at baseline resulted in modest long-term naïve T-cell recovery. CONCLUSIONS Patients with prolonged undetectable plasma HIV-1 RNA levels during antiretroviral therapy do not invariably show immune restoration. Naïve T-cell recovery in the setting of complete viral suppression is a gradual process, similar to that reported for immune recovery in adults after chemotherapy and bone marrow transplantation.
Collapse
Affiliation(s)
- N G Pakker
- Department of Clinical Viro-Immunology, CLB, Sanquin Blood Supply Foundation, University of Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Koopmans PP, Burger DM. Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Pharm World Sci 1998; 20:253-7. [PMID: 9972526 DOI: 10.1023/a:1008617019897] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Drug reactions in patients with HIV infection, e.g. fever or rash, are a frequently occurring clinical problem. These side effects particularly are observed with sulfonamides; however, many other drugs have also shown to induce allergic reactions when given to patients with HIV infection. The production of hydroxylamines has been put forward as one of the explanations for these high incidence of reactions on drugs. Since sulfonamides are the first choice of therapy for the treatment and prophylaxis of Pneumocystis carinii pneumonia, several strategies have been developed to circumvent drug reactions. In general rechallenge or desensitization are recommended in literature. This article discusses the results and risks of rechallenge and desensitization with sulfonamides or other drugs, as mentioned in the literature. Furthermore preliminary results of rechallenge with a sulfonamide, which is not metabolized into hydroxylamines, are presented. From the data in the literature it is concluded that desensitization should be preferred to rechallenge.
Collapse
Affiliation(s)
- P P Koopmans
- Department of General Internal Medicine, University Hospital Nijmegen St. Radboud, The Netherlands
| | | |
Collapse
|
50
|
|